FDA Grants PMA Approval for Hologic's Aptima® HIV-1 Quant Assay
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Piper Jaffray Upgrades Hologic (HOLX) to Overweight
January 4, 2017 6:44 AM ESTPiper Jaffray upgraded Hologic (NASDAQ: HOLX) from Neutral to Overweight with a price target of $48.00 (from $44.00).
For an analyst ratings summary and ratings history on Hologic click here. For more ratings news on Hologic click here.
Shares of Hologic closed at $40.15 yesterday.
... More